GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Net Margin %

OCS (Oculis Holding AG) Net Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Oculis Holding AG's Net Income for the three months ended in Sep. 2024 was $-23.83 Mil. Oculis Holding AG's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Oculis Holding AG's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Oculis Holding AG's Net Margin % or its related term are showing as below:


OCS's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -140.3
* Ranked among companies with meaningful Net Margin % only.

Oculis Holding AG Net Margin % Historical Data

The historical data trend for Oculis Holding AG's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Net Margin % Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Margin %
- - - -

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oculis Holding AG's Net Margin %

For the Biotechnology subindustry, Oculis Holding AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oculis Holding AG's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Net Margin % distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Net Margin % falls into.



Oculis Holding AG Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Oculis Holding AG's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-102.685/0
= %

Oculis Holding AG's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-23.831/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oculis Holding AG  (NAS:OCS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Oculis Holding AG Net Margin % Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.